A Systematic Review and Meta-Analysis on Metabolic Bone Disease in Patients with Primary Sclerosing Cholangitis
Data about the association between primary sclerosing cholangitis (PSC) and metabolic bone disease are still unclear. PSC is a chronic cholestatic liver disease (CCLD) which affects the biliary tract, and it has a highly variable natural history. We systematically searched until 28 February 2022 MED...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-06-01
|
| Series: | Journal of Clinical Medicine |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2077-0383/11/13/3807 |
| _version_ | 1797443021446316032 |
|---|---|
| author | Claudiu Marinel Ionele Adina Turcu-Stiolica Mihaela Simona Subtirelu Bogdan Silviu Ungureanu George Ovidiu Cioroianu Ion Rogoveanu |
| author_facet | Claudiu Marinel Ionele Adina Turcu-Stiolica Mihaela Simona Subtirelu Bogdan Silviu Ungureanu George Ovidiu Cioroianu Ion Rogoveanu |
| author_sort | Claudiu Marinel Ionele |
| collection | DOAJ |
| description | Data about the association between primary sclerosing cholangitis (PSC) and metabolic bone disease are still unclear. PSC is a chronic cholestatic liver disease (CCLD) which affects the biliary tract, and it has a highly variable natural history. We systematically searched until 28 February 2022 MEDLINE, Cochrane Central Register of Controlled Trials, the ISI Web of Science, and SCOPUS, for studies in patients with PSC. We identified 343 references to potential studies. After screening them, we included eight studies (893 PSC patients, 398 primary biliary cirrhosis (PBC) patients, and 673 healthy controls) for the present meta-analysis. Pooled analyses found no difference in BMD-LS (Z = 0.02, <i>p</i>-value = 0.98) between PSC patients and healthy controls. BMD-LS was statistically lower in PBC patients than in PSC patients (Mean Difference, MD, 0.06, 95% CI 0.03 to 0.09, <i>p</i>-value = 0.0007). The lumbar spine T-score was higher in the PSC patients compared with PBC patients (MD 0.23, 95% CI 0.04 to 0.42, <i>p</i>-value = 0.02). Given the limited literature available, better designed, and larger scale primary studies will be required to confirm our conclusion. |
| first_indexed | 2024-03-09T12:50:04Z |
| format | Article |
| id | doaj.art-7a3fe5bdefe041d38bdda377024aa0bf |
| institution | Directory Open Access Journal |
| issn | 2077-0383 |
| language | English |
| last_indexed | 2024-03-09T12:50:04Z |
| publishDate | 2022-06-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Clinical Medicine |
| spelling | doaj.art-7a3fe5bdefe041d38bdda377024aa0bf2023-11-30T22:07:36ZengMDPI AGJournal of Clinical Medicine2077-03832022-06-011113380710.3390/jcm11133807A Systematic Review and Meta-Analysis on Metabolic Bone Disease in Patients with Primary Sclerosing CholangitisClaudiu Marinel Ionele0Adina Turcu-Stiolica1Mihaela Simona Subtirelu2Bogdan Silviu Ungureanu3George Ovidiu Cioroianu4Ion Rogoveanu5Doctoral School, University of Medicine and Pharmacy of Craiova, 200349 Craiova, RomaniaDepartment of Pharmacoeconomics, University of Medicine and Pharmacy of Craiova, 200349 Craiova, RomaniaDepartment of Pharmacoeconomics, University of Medicine and Pharmacy of Craiova, 200349 Craiova, RomaniaResearch Center of Gastroenterology and Hepatology, University of Medicine and Pharmacy of Craiova, 200638 Craiova, RomaniaDoctoral School, University of Medicine and Pharmacy of Craiova, 200349 Craiova, RomaniaResearch Center of Gastroenterology and Hepatology, University of Medicine and Pharmacy of Craiova, 200638 Craiova, RomaniaData about the association between primary sclerosing cholangitis (PSC) and metabolic bone disease are still unclear. PSC is a chronic cholestatic liver disease (CCLD) which affects the biliary tract, and it has a highly variable natural history. We systematically searched until 28 February 2022 MEDLINE, Cochrane Central Register of Controlled Trials, the ISI Web of Science, and SCOPUS, for studies in patients with PSC. We identified 343 references to potential studies. After screening them, we included eight studies (893 PSC patients, 398 primary biliary cirrhosis (PBC) patients, and 673 healthy controls) for the present meta-analysis. Pooled analyses found no difference in BMD-LS (Z = 0.02, <i>p</i>-value = 0.98) between PSC patients and healthy controls. BMD-LS was statistically lower in PBC patients than in PSC patients (Mean Difference, MD, 0.06, 95% CI 0.03 to 0.09, <i>p</i>-value = 0.0007). The lumbar spine T-score was higher in the PSC patients compared with PBC patients (MD 0.23, 95% CI 0.04 to 0.42, <i>p</i>-value = 0.02). Given the limited literature available, better designed, and larger scale primary studies will be required to confirm our conclusion.https://www.mdpi.com/2077-0383/11/13/3807primary sclerosing cholangitischolestasisosteopeniaosteoporosis |
| spellingShingle | Claudiu Marinel Ionele Adina Turcu-Stiolica Mihaela Simona Subtirelu Bogdan Silviu Ungureanu George Ovidiu Cioroianu Ion Rogoveanu A Systematic Review and Meta-Analysis on Metabolic Bone Disease in Patients with Primary Sclerosing Cholangitis Journal of Clinical Medicine primary sclerosing cholangitis cholestasis osteopenia osteoporosis |
| title | A Systematic Review and Meta-Analysis on Metabolic Bone Disease in Patients with Primary Sclerosing Cholangitis |
| title_full | A Systematic Review and Meta-Analysis on Metabolic Bone Disease in Patients with Primary Sclerosing Cholangitis |
| title_fullStr | A Systematic Review and Meta-Analysis on Metabolic Bone Disease in Patients with Primary Sclerosing Cholangitis |
| title_full_unstemmed | A Systematic Review and Meta-Analysis on Metabolic Bone Disease in Patients with Primary Sclerosing Cholangitis |
| title_short | A Systematic Review and Meta-Analysis on Metabolic Bone Disease in Patients with Primary Sclerosing Cholangitis |
| title_sort | systematic review and meta analysis on metabolic bone disease in patients with primary sclerosing cholangitis |
| topic | primary sclerosing cholangitis cholestasis osteopenia osteoporosis |
| url | https://www.mdpi.com/2077-0383/11/13/3807 |
| work_keys_str_mv | AT claudiumarinelionele asystematicreviewandmetaanalysisonmetabolicbonediseaseinpatientswithprimarysclerosingcholangitis AT adinaturcustiolica asystematicreviewandmetaanalysisonmetabolicbonediseaseinpatientswithprimarysclerosingcholangitis AT mihaelasimonasubtirelu asystematicreviewandmetaanalysisonmetabolicbonediseaseinpatientswithprimarysclerosingcholangitis AT bogdansilviuungureanu asystematicreviewandmetaanalysisonmetabolicbonediseaseinpatientswithprimarysclerosingcholangitis AT georgeovidiucioroianu asystematicreviewandmetaanalysisonmetabolicbonediseaseinpatientswithprimarysclerosingcholangitis AT ionrogoveanu asystematicreviewandmetaanalysisonmetabolicbonediseaseinpatientswithprimarysclerosingcholangitis AT claudiumarinelionele systematicreviewandmetaanalysisonmetabolicbonediseaseinpatientswithprimarysclerosingcholangitis AT adinaturcustiolica systematicreviewandmetaanalysisonmetabolicbonediseaseinpatientswithprimarysclerosingcholangitis AT mihaelasimonasubtirelu systematicreviewandmetaanalysisonmetabolicbonediseaseinpatientswithprimarysclerosingcholangitis AT bogdansilviuungureanu systematicreviewandmetaanalysisonmetabolicbonediseaseinpatientswithprimarysclerosingcholangitis AT georgeovidiucioroianu systematicreviewandmetaanalysisonmetabolicbonediseaseinpatientswithprimarysclerosingcholangitis AT ionrogoveanu systematicreviewandmetaanalysisonmetabolicbonediseaseinpatientswithprimarysclerosingcholangitis |